HBM Holdings Limited
HKEX:2142.HK
Overview | Financials
Company Name | HBM Holdings Limited |
Symbol | 2142.HK |
Currency | HKD |
Price | 1.19 |
Market Cap | 914,962,440 |
Dividend Yield | 0% |
52-week-range | 1.01 - 1.98 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Jingsong Wang M.D., Ph.D. |
Website | https://www.harbourbiomed.com |
An error occurred while fetching data.
About HBM Holdings Limited
HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; Tanfanercept (HBM9036) to treat moderate to-severe dry
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD